ceric oxide has been researched along with Colitis Gravis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Chen, B; Gao, Y; Hu, D; Liu, K; Wang, K; Wen, J; Zhang, Y; Zhao, X; Zou, J | 1 |
| Bi, Y; Ding, H; Gou, J; He, H; Ji, M; Liu, H; Tang, X; Xiao, P; Yin, T; Zhang, Y; Zhao, J | 1 |
| Asgharzadeh, F; Avan, A; Hashemzadeh, A; Khazaei, M; Mehr, SMH; Nazari, SE; Rahmani, F; Soleimanpour, S; Yaghoubi, A | 1 |
3 other study(ies) available for ceric oxide and Colitis Gravis
| Article | Year |
|---|---|
Hyaluronic acid/serotonin-decorated cerium dioxide nanomedicine for targeted treatment of ulcerative colitis.
Topics: Animals; Colitis, Ulcerative; Disease Models, Animal; Hyaluronic Acid; Hydrogen Peroxide; Inflammation; Nanomedicine; Reactive Oxygen Species; Serotonin | 2023 |
Integration of MyD88 inhibitor into mesoporous cerium oxide nanozymes-based targeted delivery platform for enhancing treatment of ulcerative colitis.
Topics: Animals; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Inflammation; Mice; Myeloid Differentiation Factor 88; NF-kappa B; Reactive Oxygen Species | 2023 |
Cerium oxide nanoparticles acts as a novel therapeutic agent for ulcerative colitis through anti-oxidative mechanism.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cerium; Colitis, Ulcerative; Colon; Dextran Sulfate; Free Radical Scavengers; Free Radicals; Male; Metal Nanoparticles; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Nanomedicine; Oxidative Stress; Spectroscopy, Fourier Transform Infrared; Sulfasalazine; Superoxide Dismutase; X-Ray Diffraction | 2021 |